ICOTYDE - Concomitant Use with Thyroid Medications in Patients with Plaque Psoriasis

SUMMARY

• The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.

company core data sheet

Drug Interactions

• No formal drug-drug interaction studies have been conducted with ICOTYDE.¹
• Based on in vitro studies, icotrokinra is not a CYP enzyme substrate, inhibitor, or inducer. Icotrokinra is not a substrate or inhibitor of P-glycoprotein (P-gp) or other major drug transporters. Therefore, no clinically relevant drug interactions have been identified.¹

CLINICAL TRIAL PROTOCOLS

Bissonnette et al (2025)², Gooderham et al (2025)³, and Stein Gold et al (2025)⁴ included the following protocol language for ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2.

Prior and Concomitant Therapy

• Thyroid medications were not prohibited during the ICONIC phase 3 trials.^2-4
• Modification of an effective pre-existing therapy was not made for the explicit purpose of entering a patient into the studies.^2-4

Concomitant Medications

• Review of concomitant therapies was completed at every study visit during the screening period (weeks -5 to 0); at weeks 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 44, and 52; and at any unscheduled visit per the investigator’s discretion.^2-4

CLINICAL Data

ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, ICONIC-TOTAL, and ICONIC-LEAD

• Data on patients randomized to ICOTYDE with reported use of thyroid medications is summarized in Table: Patients with Concomitant Thyroid Medications (Based on Data through Week 52).

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 22 July 2026.